French biopharmaceutical company Genfit has begun patient enrolment for the Phase IIa clinical trial of elafibranor to treat primary biliary cholangitis (PBC).

Elafibranor is an oral once-daily that acts through proliferator-activated alpha / delta pathways.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Specifically developed for non-alcoholic steatohepatitis (NASH), the drug is expected to work on different aspects of the disease such as inflammation, insulin sensitivity, lipid / metabolic profile, and liver markers.

The multi-centre, double-blind, randomised, placebo-controlled Phase IIa trial is designed to recruit a total of 45 patients.

Set to be conducted at sites in the US and three European countries, the trial will assess the efficacy and safety of 80mg or 120mg of elafibranor for a period of 12 weeks in adult patients who have shown inadequate response to ursodeoxycholic acid (UDCA).

See Also:
"We are excited to have this first randomised PBC patient in this Phase II trial and advance our PBC programme."

Genfit chief medical officer Sophie Mégnien said: “We are excited to have this first randomised PBC patient in this Phase II trial and advance our PBC programme.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Elafibranor, a dual PPAR alpha and delta agonist, is an attractive candidate for PBC patients due to its impact on lowering alkaline phosphatase levels, as shown in previous studies in other populations.

"This attribute, along with what PPARs have consistently demonstrated on ALP reduction, provides a strong rationale for elafibranor in PBC."

The trial's primary objective is determination of elafibranor's effect on serum alkaline phosphatase (ALP), while secondary objectives include safety, measure of total bilirubin, PBC scores, pruritus and quality of life.